Assessment Of Psychiatric Comorbidities Associated in Cases with Cannabis Use
Authors/Creators
- 1. Associate Professor, Department of Psychiatry, MNR Medical College and Hospital, Sangareddy, Telangana, India
Description
Introduction: Cannabis is the third most commonly used psychoactive illicit substance globally after alcohol and tobacco. Cannabis use was associated with robust increases in risk for psychiatric comorbidities. The present study was designed to evaluate psychiatric comorbidities among cases with cannabis use. Material and Methods: Fifty eight cases under cannabis use attending the outpatient department of psychiatry and fulfill criteria for cannabis dependence as per ICD-10 above 15 years of age was included. Participant details were collected using semistructured patient proforma and details of cannabis dependence were collected by using marijuana problem scale, and the cannabis withdrawal scale. Results: Onset of cannabis abuse was below 18 years in 34.48% cases and above 18 years in 65.52% cases. Psychotic disorders (55%) were the common psychiatric comorbidity associated followed by Nonalcoholic psychoactive substance use disorders (NAPSD) (19%), manic episode (14%), ASPD (7%) and Depression (5%). The mean difference of comparison between duration of cannabis abuse and symptoms of cannabis withdrawal and duration of illness was statistically significant (p<0.05). Discussion and Conclusion: Cannabis abuse is a serious public health concerns requires active implementation of preventive and rehabilitation programs and educate the adolescents on the risks associated with its use.
Abstract (English)
Introduction: Cannabis is the third most commonly used psychoactive illicit substance globally after alcohol and tobacco. Cannabis use was associated with robust increases in risk for psychiatric comorbidities. The present study was designed to evaluate psychiatric comorbidities among cases with cannabis use. Material and Methods: Fifty eight cases under cannabis use attending the outpatient department of psychiatry and fulfill criteria for cannabis dependence as per ICD-10 above 15 years of age was included. Participant details were collected using semistructured patient proforma and details of cannabis dependence were collected by using marijuana problem scale, and the cannabis withdrawal scale. Results: Onset of cannabis abuse was below 18 years in 34.48% cases and above 18 years in 65.52% cases. Psychotic disorders (55%) were the common psychiatric comorbidity associated followed by Nonalcoholic psychoactive substance use disorders (NAPSD) (19%), manic episode (14%), ASPD (7%) and Depression (5%). The mean difference of comparison between duration of cannabis abuse and symptoms of cannabis withdrawal and duration of illness was statistically significant (p<0.05). Discussion and Conclusion: Cannabis abuse is a serious public health concerns requires active implementation of preventive and rehabilitation programs and educate the adolescents on the risks associated with its use.
Files
IJPCR,Vol14,Issue9,Article67.pdf
Files
(304.9 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:b2cadaee9e6d692b0e5bb19e04108c18
|
304.9 kB | Preview Download |
Additional details
Dates
- Accepted
-
2022-08-30
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/14/IJPCR,Vol14,Issue9,Article67.pdf
- Development Status
- Active
References
- 1. United Nations Office on Drugs and Crime. World Drug Report 2014. New York: United Nations Publication; 2014. 2. Ray R, editor. The Extent, Pattern and Trends of Drug Abuse in India - National Survey: New Delhi. Ministry of Social Justice and Empowerment, Government of India and UnitedNations Office on Drugs and Crime; 2004. 3. Report of the International Narcotics Control Board (2008). DIANE Publishing. May 2009: 90. 4. After alcohol, India has a rising cannabis addiction problem, warns AIIMS study. Business Insider. Retrieved 16 March 2019. 5. Infographic: Cannabis-and-opiumbased drugs cheapest in India - Times of India". The Times of India. Retrieved 14 October 2017. 6. Wilson N, Cadet JL. Comorbid mood, psychosis, and marijuana abuse disorders: a theoretical review. J Addict Dis. 2009 Oct;28(4):309-19. 7. Carra, G.; Bartoli, F.; Riboldi, I.; Trotta, G.; Crocamo, C. Poverty matters: Cannabis use among people with serious mental illness: Findings from the United States survey on drug use and health, 2015. Int. J. Soc. Psychiatry 2018, 64, 656–659. 8. Deborah Hasin, Claire Walsh Cannabis Use, Cannabis Use Disorder, and Comorbid Psychiatric Illness: A Narrative Review. J. Clin. Med. 2021; 10(15):1-19. 9. Brook JS, Lee JY, Finch SJ, Koppel J, Brook DW. Psychosocial factors related to cannabis use disorders. Subst Abus. 2011;32(4):242-51. 10. Khantzian EJ, Albanese MJ. Understanding Addiction as Self Medication: Finding Hope Behind the Pain. Lanham, MD: Rowman & Littlefield Publishers, Inc; 2008. 11. Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006; 19:233-238. 12. Budney AJ, Moore BA. Development and consequences of cannabis dependence. J Clin Pharmacol 2002; 42:28S-33S. 13. Johns A. Psychiatric effects of cannabis. Br Journal of Psychiatry 2001; 178:116-122. 14. Kouri EM, Pope HG. Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharmacol 2000; 8:483-492. 15. Block RI, O'Leary DS, Hichwa RD, Augustinack JC, Ponto LLB, Ghoneim MM, Arndt S, Hurtig RR, Watkins GL, Hall JA, Nathan PE, Andreasen NC. Effects of frequent marijuana use on memory-related regional cerebral blood flow. Pharmacol Biochem Behav 2002; 72:237–250. 16. Eldreth DA, Matochik JA, Cadet JL, Bolla KI. Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. Neuroimaging 2004; 23:914–920. 17. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology 2000;59(9):1337–1343. 18. Bolla KI, Eldreth DA, Matochik JA, Cadet JL. Neural substrates of faulty decision-making in abstinent marijuana users. NeuroImage 2005; 26:480–492. 19. Jager G, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology 2006;185(3):358–368. 20. Subbaraman MS, Kerr WC. Simultaneous versus concurrent use of alcohol and cannabis in the National Alcohol Survey. Alcohol. Clin. Exp. Res. 2015; 39:872–879. 21. Marconi A, di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophr. Bull. 2016; 42:1262–1269. 22. Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, Bianconi F, Gardner-Sood P. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study. Lancet Psychiatry 2015; 2:233–238. 23. Moore T, Zammit S, Lingford-Hughes A, Barnes T, Jones P, Burke M, LewisG. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. The Lancet 2007;370(9584):319-328. 24. Zammit S, Owen M, Evans J, Heron J, Lewis G. Cannabis, COMT and psychotic experiences. The British Journal of Psychiatry 2011;199(5): 380-385. 25. Caspi A, Moffitt T, Cannon M, McClay J, Murray R., Harrington H, Craig, IW. Moderation of the Effect of Adolescent-Onset Cannabis Use on Adult Psychosis by a Functional Polymorphism in the Catechol-OMethyltransferase Gene: Longitudinal Evidence of a Gene X Environment Interaction. Biological Psychiatry 2005;57(10): 1117-1127.